EU/3/16/1811

About

On 12 January 2017, orphan designation (EU/3/16/1811) was granted by the European Commission to Centre Hospitalier Universitaire de Lille, France, for 5-aminolevulinic acid for the treatment of glioma.

Key facts

Active substance
5-aminolevulinic acid
Medicine name
-
Disease / condition
Treatment of glioma
Date of first decision
12/01/2017
Outcome
Positive
EU designation number
EU/3/16/1811

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Centre Hospitalier Universitaire de Lille
2, avenue Oscar Lambret
59037 Lille Cedex
France
Tel. +33 20 44 67 21
E-mail: m-vermandel@chru-lille.fr

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating